Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Lung
Study Name
S1800A (LungMAP Sub-study): A Phase II Randomized Study of Ramucirumab Plus Mk3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
Principal Investigator
Gordan Srkalovic
Study Information
https://clinicaltrials.gov/ct2/show/NCT03971474
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance